Trevi Therapeutics Inc (NAS:TRVI)
$ 3.3 0 (0%) Market Cap: 239.55 Mil Enterprise Value: 171.25 Mil PE Ratio: 0 PB Ratio: 3.62 GF Score: 41/100

Trevi Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 17, 2023 / 03:00PM GMT
Release Date Price: $1.85 (-2.12%)
Serge Belanger
Needham & Company, LLC - Analyst

Good morning, and welcome to Needham's 22nd Annual Healthcare Conference. I'm Serge Belanger, one of the senior healthcare analysts at Needham. And happy to have our next session, the Trevi Therapeutics team. We have CEO, Jennifer Good; CFO, Lisa Delfini; and the new Chief Medical Officer, David Clark. (Conference Instructions)

So Jennifer, I'll hand it over to you for just a quick overview.

Jennifer Good
Trevi Therapeutics, Inc. - Co-Founder, President & CEO

Sounds great, Serge. Thank you for having us. We're appreciative of our partnership with Needham. Trevi came off a big year in 2022. I'm one of the two co-founders.

So we've been on a journey, proving out the mechanism of the drug, that I presume we'll talk more about in the fireside chat. We had two key programs going on, one within a severe pruritus condition called prurigo nodularis; and the other was an exploratory program in cough in idiopathic pulmonary fibrosis, which has been quite difficult and there have been some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot